Functional and Structural Outcomes of Temporal Zone II-Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab in Retinopathy of Prematurity
Table 2
Comparison of treatment outcomes, ocular complications, and refractive errors.
Temporal-sparing LIO + IVB
LIO alone
value
Early treatment outcome
Plus sign disappeared (%)
32 (100)
42 (100)
Time to plus sign regression (days)
12.1 ± 6.2
25.6 ± 21.3
0.011‡
Retreatment (%)
0 (0)
10 (23.8)
0.004†
Time to retreatment (days)
25.0 ± 14.4
Retinal/preretinal hmr (%)
3 (9.4)
18 (42.9)
0.002
Vitreous hmr (%)
0 (0)
4 (9.5)
0.129†
Ocular inflammation (%)
0 (0)
0 (0)
Endophthalmitis (%)
0 (0)
0 (0)
Adverse systemic safety issues (%)
0 (0)
0 (0)
Late complications
Macular dragging (%)
0 (0)
5 (11.9%)
0.065†
Optic disc atrophy (%)
4 (12.5)
8 (19.0%)
0.449
Strabismus (%)
10 (31.3)
14 (33.3)
0.850
Nystagmus (%)
6 (18.8)
6 (14.3)
0.606
Amblyopia (%)
8 (25.0)
10 (23.8)
0.906
Cataract (%)
0 (0)
0 (0)
Microcornea (%)
0 (0)
0 (0)
Angle closure glaucoma (%)
0 (0)
0 (0)
Refractive errors
Measurement period (months)
9.7 ± 4.2
11.0 ± 5.6
0.464‡
Spherical equivalent (D)
−0.43 ± 0.58
−0.94 ± 2.69
0.293‡
Emmetropia (%)
7 (21.9)
16 (38.0)
0.130
Mild myopia (0–3 D) (%)
20 (62.5)
22 (52.4)
Moderate myopia (3–6 D) (%)
0 (0)
0 (0)
High myopia (>6 D) (%)
0 (0)
2 (4.8)
Hyperopia (%)
5 (15.6)
2 (4.8)
Continuous variables are shown as mean ± SD; chi-square analysis; †Fisher’s exact test; ‡Student’s t-test; hmr, haemorrhage.
